BioSeek Initiates Research Collaboration with Lexicon Pharmaceuticals
Complete the form below to unlock access to ALL audio articles.
BioSeek, Inc. has announced the initiation of a research collaboration with Lexicon Pharmaceuticals, Inc. Under the agreement, BioSeek’s BioMAP® Systems will be used to help further evaluate selected compounds associated with several of Lexicon’s drug discovery programs.
“This research collaboration with Lexicon leverages the power of our BioMAP Systems to speed the characterization of targets identified by genomic approaches and the discovery of drugs to modulate them,” said Michael C. Venuti, Ph.D., Chief Executive Officer of BioSeek.
“By providing predictive preclinical human data on the pharmacological properties of Lexicon’s compounds, the BioMAP platform can help to discern the relevant physiologic pathway impacted by the compounds and identify appropriate cellular assays for their further optimization,” Venuti added.
BioMAP Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. To date, BioSeek has developed systems for indications in vascular inflammation, cardiovascular and respiratory diseases, fibrosis and related conditions.
Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in BioSeek’s database. BioMAP profiling provides early insight into human pharmacological properties of compounds, including in-depth characterization of biological drug function, on- and off-target activities, dose responses and biomarker identification.
